anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aging-related abnormalities in gut microbiota are associated with cognitive decline, depression, and anxiety, but underlying mechanisms remain unstudied. Here, our study demonstrated that transplanting old gut microbiota to young mice induced inflammation in the gut and brain coupled with cognitive decline, depression, and anxiety. We observed diminished mucin formation and increased gut permeability ("leaky gut") with a reduction in beneficial metabolites like butyrate because of decline in butyrate-producing bacteria in the aged gut microbiota. This led to suppressed expression of butyrate receptors, free fatty acid receptors 2 and 3 (FFAR2/3). Administering butyrate alleviated inflammation, restored mucin expression and gut barriers, and corrected brain dysfunction. Furthermore, young mice with intestine-specific loss of FFAR2/3 exhibited gut and brain abnormalities akin to those in older mice. Our results demonstrate that reduced butyrate-producing bacteria in aged gut microbiota result in low butyrate levels and reduced FFAR2/3 signaling, leading to suppressed mucin formation that increases gut permeability, inflammation, and brain abnormalities. These findings underscore the significance of butyrate-FFAR2/3 agonism as a potential strategy to mitigate aged gut microbiota-induced detrimental effects on gut and brain health in older adults.
Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.
Disclosed is a method and a system for sharing medical records data of a patient with a home medical equipment provider entity and a physician entity using a computerized records management system (110) on a network (160). The medical records data at least includes data associated with a home medical equipment (HME) device (170) provided to the patient. The method comprises the steps of creating a HME device associated patient record in the computerized records management system (110); associating the HME device associated patient record with at least one of the home medical equipment provider entity and the physician entity; and transmitting, via the network (160), data of the HME device associated patient record to a device (140, 150) associated with the home medical equipment provider entity or the physician entity. The HME device associated patient record comprises patient information and an HME device identifier. Wherein the HME device identifier is associated with the HME device (130) and is a unique identifier that distinguishes the HME device (130) provided to the patient from other HME devices registered at the computerized records management system (110). The computerized records management system (110) is configured to provide access to the patient information via the HME device associated patient record in connection with an HME device identifier search, whereby duplicate record creation is avoided.
OBJECTIVE: To develop and validate a clinical-radiomics nomogram for predicting early ischemic stroke risk in patients who sustain a transient ischemic attack (TIA).
METHODS: A retrospective training dataset (n = 76) and a prospective validation dataset (n = 34) of patients with TIA were studied. Image processing was performed using ITK-snap and Artificial Intelligent Kit. Radiomics features were selected in R. A nomogram predicting recurrent TIA/stroke in 90 days as a recurrent ischemic event was established. Model performance was assessed by computing the receiver operating characteristic curve and decision curve analysis (DCA).
RESULTS: We found a higher proportion of diabetes and hypertension in the patients with recurrent TIA compared with the stable patients in both the training and validation datasets (P < 0.05). Recurrent patients had significantly higher ABCD2 scores and plaque scores compared to stable patients. ABCD2 score and necrotic/lipid core area were independent risk factors for recurrent ischemic events (odds ratio [OR], 2.75; 95% confidence interval [CI], 1.47-6.40; and OR, 1.20; 95% CI, 1.07-1.41, respectively). The radiomics model had area under the curve values of 0.737 (95% CI, 0.715-0.878) in the training dataset and 0.899 (95% CI, 0.706-0.936) in the validation dataset, which was superior to the ABCD2 score and plaque model for predicting stroke recurrence (P < 0.05). The nomogram predicting recurrent ischemic events was 0.923 (95% CI, 0.895-0.978) in the training dataset and 0.935 (95% CI, 0.830-0.959) in the validation dataset. DCA confirmed the clinical value of this nomogram.
CONCLUSIONS: The nomogram, based on clinical ABCD2 score, carotid plaque components and radiomics score, shows good performance in predicting the risk of recurrent ischemic events in patients with TIA.
In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity \< 6.8NBT were positive, and G6PD deficiency is confirmed.
Type 2 diabetes is a metabolic disorder characterized by elevated fasting blood glucose and impaired insulin signaling (insulin resistance) and is associated with several comorbidities including neuropathy, retinopathy, kidney disease, and elevated risk for heart attack and stroke. Lifestyle interventions targeted towards prevention of type 2 diabetes include: maintaining and achieving healthy bodyweight, physical activity, avoiding tobacco use, and reducing sugar and saturated fat intake. The International Scientific Consensus Summit from the International Carbohydrate Quality Consortium indicated that diets low in glycemic index and glycemic load were important in the prevention and management of diabetes. Health supplements that can lower the glycemic index and glycemic load of food have potential to support the prevention of diabetes and improve blood glucose management by reducing post prandial glycemia and insulinemia. This project will test a unique botanical formula designed to inhibit alpha amylase (the primary starch degrading digestive enzyme) and inhibit sucrase (the primary sucrose degrading digestive enzyme) in order to reduce acute post prandial glycemia regardless of nutritive carbohydrate source. This proposal will fill a void in the literature by testing for the first time the effect of a combination of mulberry leaf, white kidney bean extract and cinnamon on postprandial carbohydrate absorption and glucose control in overweight, insulin resistant men and women. This project will provide pilot data to support larger studies, and studies to investigate long-term effects.
PROBLEM TO BE SOLVED: To provide a germicidal composition which is proper of being utilized in various facilities such as a food service industry, a hospital, a school and a livestock factory, a home, etc., and is improved in sterilizing power, and to provide a sterilizing power-promoting method for further promoting the sterilizing power of hinokitiol. SOLUTION: This germicidal composition comprises 100 pts.wt. of hinokitiol and/or its salt and 400-20,000 pts.wt. of an inorganic salt. The sterilizing power- promoting method for enhancing the sterilizing power of the composition is to formulate 100 pts.wt. of hinokitiol and/or its salt with 400-20,000 pts.wt. of an inorganic salt.
CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
Patients receive obinutuzumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, and 24. Patients also receive venetoclax PO QD on days 1-28 (days 4-28 of cycle 1) and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Research has demonstrated an association between elevated systemic inflammation and changes in brain function. Affective areas of the brain involved in processing threat (e.g., amygdala) and reward (e.g., nucleus accumbens) appear to be sensitive to inflammation. Early-life stress, such as experiencing low socioeconomic status (SES), may also potentiate this association, but relevant evidence has come primarily from cross-sectional studies of brain function. It is unclear whether similar associations are present between early-life stress, inflammation, and brain structure, particularly in typically developing populations.
METHODS: We recruited and assessed 50 adolescents (31 females/19 males) from the community (mean [SD] age = 15.5 [1.1] years, range = 13.1-17.5 years) and examined in exploratory analyses whether changes in C-reactive protein (ΔCRP) from blood spots predict changes in gray matter volume (ΔGMV) in the bilateral amygdala and nucleus accumbens over a 2-year period. We also investigated whether experiencing early-life stress, operationalized using a comprehensive composite score of SES disadvantage at the family and neighborhood levels, significantly moderated the association between ΔCRP and ΔGMV.
RESULTS: We found that ΔCRP was negatively associated with Δamygdala GMV (i.e., increasing CRP levels were associated with decreasing amygdala volume; β = -0.84, p = .012). This effect was stronger in youths who experienced greater SES disadvantage (β = -0.56, p = .025).
CONCLUSIONS: These findings suggest that increases in systemic inflammation are associated with reductions in amygdala GMV in adolescents, potentially signaling accelerated maturation, and that these neuroimmune processes are compounded in adolescents who experienced greater SES disadvantage. Our findings are consistent with theoretical frameworks of neuroimmune associations and suggest that they may influence adolescent neurodevelopment.
Patients undergo SRS within 30 days of randomization followed by surgery within 30 days. Patients may undergo additional SRS if disease returns after treatment.
Variability in pain sensitivity is a well known phenomena. Clinicians involved in the care of post-surgical patients are very familiar with this variation in sensitivity. The variability also extends to experimental pain stimuli (e.g., a thermal pulse to the forearm) and can be demonstrated with normal volunteers. In our clinic, variation in the intensity and onset of acute pain in the oral surgery model, in subjects matched for similar levels of tissue injury ranges from little or no post-operative pain to reports of severe pain unrelieved by standard analgesics. While a variety of factors may account for the variability such as race or gender (Gordon 1998), preclinical data indicate that genetic factors profoundly influence pain sensitivity. Thus, the proposed study seeks to investigate genetic contributions to acute experimental and clinical post-operative pain. We have recently shown a strong correspondence between pain reports using thermal heat stimuli and post-operative pain reports. This observation has given us an important quantitative screening tool for genetic analysis of a moderate-sized cohort of subjects that has direct clinical relevance. Normal subjects and their siblings and/or parents will undergo two somatosensory tests to determine pain phenotype and will provide a blood sample which will be analyzed for genetic polymorphisms contributing to sensitivity to pain. Some of these subjects will also be candidates for the oral surgery protocol and similar pain ratings will be obtained from them post-operatively. The initial study will examine known polymorphisms for candidate genes that code for pain sensing and pain suppressing molecules.
The invention relates to an ultrahigh pressure extraction method of asparagus saponin, and belongs to the technical field of natural products. The process of the ultrahigh pressure extraction method of the asparagus saponin includes the steps of raw material processing, drying and grinding, degreasing, ultrahigh pressure extracting, separating and purifying, and reducing pressure and evaporating to dryness. The step of the ultrahigh pressure extracting is mainly optimized and improved, the ultrahigh pressure extracting technology and the macroporous resin adsorption technology are combined to be applied to the production of the asparagus saponin, the technical problems in the production of the asparagus saponin are solved effectively, the asparagus saponin which is produced has the advantages of being high in safety performance, good in wettability, strong on expansion performance, good in adhesive ability, and the like. Meanwhile, moisture is not easy to adsorb for the asparagus saponin. In addition, extraction time is short, extraction efficiency is high, energy consumption is little, extraction temperature is low, activity of effective constituent is high, and the extraction method is environment-friendly and free of pollution. The asparagus saponin can be effectively extracted from asparagus plants and scraps, and amino acid can also be extracted from the asparagus plants and the scraps.
<P>PROBLEM TO BE SOLVED: To obtain new compounds useful as pharmaceuticals, in particular histone deacetylase(HDAC) inhibitors.  <P>SOLUTION: The new compounds, i.e., new azumamides or pharmaceutically acceptable salts thereof as components extracted from Mycale izuensis as a kind of sponge, have each HDAC inhibitory activity and also cell proliferation inhibitory activity for human cancer cells, therefore are useful in treating or ameliorating diseases or palhemas associated with histone acetylation, in particular tumor or cell proliferation-related diseases. These cell prolifration-related diseases include infectious diseases, autoimmune diseases and dermatoses. In particular, since having high cell proliferation inhibitory activity against human cancer cells, the new compounds are useful as antitumor agents (e.g. medicaments for colon cancer, lung cancer, breast cancer, prostatic cancer, cancer of the cervix uteri, cerebral tumor, leukemia).  <P>COPYRIGHT: (C)2003,JPO
A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
Patients with acute coronary syndrome (ACS) are at high-risk. ACS patients are commonly associated with multiple lesions or multivessel disease. Percutaneous coronary intervention (PCI) is an effective treatment for culprit lesions in ACS. Statin at high-intensity is recommended by current guidelines in order to prevent/slow the progression of non-culprit disease or restenosis. PCSK9 inhibitor serves as the most powerful medication in lowering LDL via promoting the expression of LDL receptors in the liver. However, if the combination of PCSK9 inhibitor with high-intensity statin treatment could significantly reduce the cardiovascular events in patients with ACS who underwent PCI remains unknown.
Balziva® 28 Day (norethindrone and ethinyl estradiol tablets USP) provide a continuous regimen for oral contraception derived from 21 light peach tablets composed of norethindrone, USP and ethinyl estradiol, USP to be followed by 7 white tablets of inert ingredients. The structural formulas are:

Norethindrone, USP Ethinyl Estradiol, USP

C20H26O2 M.W. 298.42 C20H24O2 M.W. 296.40

The light peach active tablets each contain 0.4 mg norethindrone, USP and 0.035 mg ethinyl estradiol, USP, and contain the following inactive ingredients: anhydrous lactose, dibasic calcium phosphate, FD&C yellow no. 6 aluminum lake, lactose monohydrate, magnesium stearate, povidone and sodium starch glycolate. The white tablets contain only inert ingredients as follows: lactose monohydrate, magnesium stearate, and pregelatinized corn starch.
A method provides fully autonomous patient matching by entities of a federated healthcare system. The method includes receiving an electronically formatted query for a patient from an autonomous healthcare entity in a federation of healthcare entities. The query includes at least an identifier of the entity, a unique patient identifier of the patient generated by the entity, and demographics of the patient. The method further includes searching a federated master patient index stored in master patient index storage for an entry likely to correspond to the patient. The method further includes identifying an entry for the patient. The method further includes updating the identified entry to include at least the identifier of the entity, the unique patient identifier of the patient generated by the entity and the demographics.
Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
As with all oligonucleotides, including RIVFLOZA, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. 

Across all clinical studies in the nedosiran development program, including patients with PH1 dosed with RIVFLOZA, RIVFLOZA did not induce or boost anti-drug antibodies (ADA). Among 59 patients tested with the ADA assay, none developed treatment-emergent ADA.
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
The method for treating the threat of miscarriage complicated by the placental insufficiency comprises the complex medicamentous treatment. Two complexes are administered consecutively. The first complex comprises cocarboxylase 100 mg intramuscularly once a day; riboflavin mononucleotide 1%, 1.0 intramuscularly; calcium pantothenate 0.2 g thrice a day; lipoic acid 0.025 g thrice a day; alpha tocopherol acetate, one capsule twice a day. The second complex comprises riboxin 0.2 g thrice a day; pyridoxal phosphate 0.02 g thrice a day; folic acid 0.001 g thrice a day; calcium glycerophosphate 0.25 g thrice a day; potassium orotate 0.25 g thrice a day. Each complex is used for 5-7 days. The complexes are to be administered consecutively for 10-14 days with 2-3-weeks interval.
The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
Emerging evidence suggests a beneficial role of rhizobacteria in ameliorating plant disease resistance in an environment-friendly way. In this study, we characterize a rhizobacterium, Bacillus cereus NJ01, that enhances bacterial pathogen resistance in rice and Arabidopsis. Transcriptome analyses show that root inoculation of NJ01 induces the expression of salicylic acid (SA)- and abscisic acid (ABA)-related genes in Arabidopsis leaves. Genetic evidence showed that EDS1, PAD4, and WRKY18 are required for B. cereus NJ01-induced bacterial resistance. An EDS1-PAD4 complex interacts with WRKY18 and enhances its DNA binding activity. WRKY18 directly binds to the W box in the promoter region of the SA biosynthesis gene ICS1 and ABA biosynthesis genes NCED3 and NCED5 and contributes to the NJ01-induced bacterial resistance. Taken together, our findings indicate a role of the EDS1/PAD4-WRKY18 complex in rhizobacteria-induced disease resistance.
PURPOSE:The titled novel substance, containing microbial cells obtained by extracting mechanically crushed microbial cells of hemolytic streptococci as an active constituent, and useful as an anticancer agent with low toxicity. CONSTITUTION:A novel anticancer substance which is a constituent component of mirobial cells obtained by extracting mechanically crushed microbial cells of homolytic streptococci exhibiting the following properties: The molecular weight measured by the gel filtration column chromatography is higher than that of bovin blood serumal albumin (67,000) average molecular weight), and lower than that of bovin gamma-blobulin (160,000 average molecular weight). The isoelectric point is >=4 and <=5. The substance exhibits the properties of glycoprotein determined by the periodic acid Schiff (PAS) staining method. 0.5-0.6 Rf value (measured by the electrophoretic method with 7.5% polyacrylamide gel). The substance contains aspartic acid, glutamic acid, valine, isoleucine, lysine and arginine measured by the analysis of the amino acids. The substance can be administered orally and parenterally as an anticancer agent and exhibits improved anticancer activity.